Over 500,000 incident or recurrent venous thromboembolism (VTE) events occur annually in the US. Almost one-quarter of acute pulmonary embolism patients suffer sudden death. To improve survival, the occurrence of VTE must be reduced. However, the incidence of VTE has increased over the last 30 years. Moreover, near universal prophylaxis of patients hospitalized for surgery or for medical illness has not reduced hospitalization-associated ...more »
No good medical therapy exists to prevent and treat post thrombotic syndrome, the most common sequlae from a deep vein thrombosis. Recent trial data suggests that compression stockings do not prevent PTS, and thrombolysis is expensive and risky. The basic mechanisms related to fibrosis of the vein wall are not well understood.
Venous Thromboembolism (VTE) afflicts nearly a million Americans yearly, has a mortality of 6-12% and has costs of more than $15 billion. Current treatment regimens, systemic anticoagulation and compression stockings, fail patients in multiple ways: risk of major bleeding episodes; failure of clot resolution in up to 50% of patients; failure to prevent the development of post-thrombotic syndrome (PTS) in up to 40% of ...more »
How do we identify new and more effective approaches to reduce the burden of venous disease and venous ulceration?